<unk> s are biomarkers of net<unk>  of<unk>  and fibrinolysis. Examples include prothrombin fragment 1+2 (F1+2), thrombin–antithrombin complex (TAT), fibrinopeptide A (FpA), fibrin monomers (FMs), plasmin-α2-antiplasmin complex (PAP), and D-dimer (DD). These compounds are<unk> s of thrombin generation (F1+2, TAT), fibrin generation (FpA, FMs), and fibrinolysis (DD, PAP).<unk> s, particularly D-dimer, are useful in the diagnosis of acute venous thromboembolism. They may also be useful in the assessment of hypercoagulability and venous thromboembolism risk. Levels of<unk> s are increased with pregnancy, with estrogen-containing birth control pills, with menopausal hormone therapy, and with high-dose parenteral estradiol therapy for prostate cancer. Transdermal estradiol appears to have less influence on<unk> s than oral estrogens in menopausal hormone therapy. Birth control pills containing estradiol or estetrol also appear to have less influence on<unk> s than ethinylestradiol-containing birth control pills.<unk> s of platelet<unk>  (primary hemostasis) include platelet factor 4 (PF4), β-thromboglobulin (β-TG), and P-selectin.
Coagulation activation marker
Fibrin degradation product
Acute-phase protein
Thrombin time
Reptilase time
Bleeding time
Activated clotting time
Prothrombin time